Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.
Front Pharmacol., 3:195 (2012)
Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: Acute and chronic effects.
Brain Stimul., Oct (2012)
Memantine as an augmentation therapy for anxiety disorders.
Case Rep Psychiatry., 2012:749796 (2012)
Metabolites: novel therapeutics or "me-too" drugs? Using desvenlafaxine as an example.
CNS Spectr., Sep;17(3):103-6 (2012)
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.
Neuropsychiatr Dis Treat., 8:123-30 (2012)
Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia.
Curr. Pharm. Des., 18(12):1580-92 (2012)
Obesity and psychotropics.
CNS Neurosci Ther., Jan;18(1):57-63 (2012)
Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions.
Ann Clin Psychiatry., May;23(2):131-40 (2011)
Treatment strategies for dosing the second generation antipsychotics.
CNS Neurosci Ther., Apr;17(2):110-7 (2011)
Psychopharmacology Today: Where are We and Where Do We Go From Here?
Mens Sana Monogr., Jan;8(1):6-16 (2010)
Weight gain, obesity, and psychotropic prescribing.
J Obes., 2011:893629 (2011)
Acamprosate calcium as augmentation therapy for anxiety disorders.
Ann Pharmacother., Dec;44(12):1930-2 (2010)
Armodafinil for fibromyalgia fatigue.
Ann Pharmacother., 44(7-8):1347-8 (2010 Jul-Aug)
Pregabalin treatment of anxiety in patients with substance use disorders.
Ann Pharmacother., May;44(5):937-8 (2010)
Psychiatric resident and attending diagnostic and prescribing practices.
Acad Psychiatry., 32(3):214-7 (2008 May-Jun)
Treatment of fibromyalgia.
Psychiatry (Edgmont)., Mar;5(3):18-21 (2008)
Gamma hydroxy butyric acid and sodium oxybate used to treat posttraumatic stress disorder.
CNS Spectr., Dec;12(12):884-6 (2007)
Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.
Curr Opin Investig Drugs., Jul;8(7):563-9 (2007)
An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder.
Ann Clin Psychiatry., 19(1):25-30 (2007 Jan-Mar)
An eight-week, open-label, prospective case series of acamprosate calcium as monotherapy for patients with comorbid anxiety symptoms and alcohol misuse: an evaluation for alcohol sobriety and anxiolysis.
Psychiatry (Edgmont)., Apr;4(4):19-20 (2007)